Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Börse: Dax stabil, Anleger warten auf Nvidia-Zahlen, Hypoport-Aktien gefragt (Manager-Magazin) +++ HYPOPORT Aktie +6,27%

NETRAMARK Aktie

 >NETRAMARK Aktienkurs 
0.735 EUR    +3.5%    (Tradegate)
Ask: 0.75 EUR / 4077 Stück
Bid: 0.735 EUR / 5427 Stück
Tagesumsatz: 4073 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
NETRAMARK Aktie über LYNX handeln
>NETRAMARK Performance
1 Woche: -6,7%
1 Monat: -10,3%
3 Monate: -31,2%
6 Monate: -25,7%
1 Jahr: +306,4%
laufendes Jahr: +3,7%
>NETRAMARK Aktie
Name:  NETRAMARK HOLDINGS INC.
Land:  Kanada
Sektor:  Elektronik / Software
ISIN/ Wkn:  CA64119M1059 / A3D5X9
Symbol/ Ticker:  PF0 (Frankfurt)
Kürzel:  FRA:PF0, ETR:PF0, PF0:GR
Index:  -
Webseite:  https://www.netramark.com..
Profil:  Netrmark Holdings Inc. is a company involved in th..
>Volltext..
Marktkapitalisierung:  61.26 Mio. EUR
Unternehmenswert:  60.22 Mio. EUR
Umsatz:  0.32 Mio. EUR
EBITDA:  -2.88 Mio. EUR
Nettogewinn:  -2.88 Mio. EUR
Gewinn je Aktie:  -0.04 EUR
Schulden:  -
Liquide Mittel:  0.72 Mio. EUR
Operativer Cashflow:  -1.78 Mio. EUR
Bargeldquote:  2.78
Umsatzwachstum:  44.88%
Gewinnwachstum:  59.32%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  NETRAMARK
Letzte Datenerhebung:  19.11.25
>NETRAMARK Kennzahlen
Aktien/ Unternehmen:
Aktien: 85.85 Mio. St.
Frei handelbar: 78.68%
Leerverk. Aktien: -
Rückkaufquote: -4.26%
Mitarbeiter: -
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Neutral
Kursziel: -
Bewertung:
KGV: -
KGV lG: -
KUV: 172.86
KBV: 81.24
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -913.49%
Operative Marge: -913.49%
Managementeffizenz:
Gesamtkaprendite: -402.65%
Eigenkaprendite: -638.24%
>NETRAMARK Peer Group

Es sind 112 Aktien bekannt.
 
18.11.25 - 14:42
 Vertragsunterzeichnung zwischen NetraMark und international führendem Pharmaunternehmen soll bessere Erkenntnisse aus klinischen Studien ermöglichen (IRW Press)
 
TORONTO, ON, 18. November 2025 / IRW-Press / NetraMark Holdings Inc. (das Unternehmen oder NetraMark) (CSE: AIAI) (OTCQB: AINMF) (FWB: PF0), ein führendes Unternehmen für künstliche Intelligenz (KI),......
18.11.25 - 14:33
 NetraMark Signs Four New Contracts With a Leading Global Pharmaceutical Company To Enhance Clinical Trial Insights (GlobeNewswire EN)
 
TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced that it has signed four contracts with a leading global pharmaceutical company to provide advanced AI analytics supporting multiple late-stage clinical studies....
03.11.25 - 14:36
 Vertragsunterzeichnung zwischen NetraMark und international führendem Biopharmaunternehmen soll bessere Erkenntnisse aus klinischen Studien ermöglichen (IRW Press)
 
TORONTO, ON, 3. November 2025 / IRW-Press / NetraMark Holdings Inc. (das Unternehmen oder NetraMark) (CSE: AIAI) (OTCQB: AINMF) (FWB: PF0), ein führendes Unternehmen für künstliche Intelligenz (KI),......
03.11.25 - 14:33
 Netramark Signs Contract with a Leading Global Biopharmaceutical Company to Enhance Clinical Trial Insights (GlobeNewswire EN)
 
TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that it has signed a new contract with a leading biopharmaceutical company to apply its NetraAI platform to a Phase 3 clinical trial of a novel psychiatric medicine....
29.10.25 - 11:33
 NetraMark Presents AI-Driven Advances in Precision Psychiatry to Enhance Clinical Trial Designs at Joint Autumn Conference (GlobeNewswire EN)
 
TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, presented two significant applications of its technology at the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn conference and the European College of Neuropsychopharmacology (ECNP) Congress. These presentations (available on NetraMark's website) showcase the power of NetraAI in major depressive disorder (MDD) clinical trials....
22.09.25 - 14:36
 NetraMark initiiert KI-Kooperation auf dem Gebiet der Glioblastom-Forschung (IRW Press)
 
TORONTO, ON, 22. September 2025 / IRW-Press / NetraMark Holdings Inc. (das Unternehmen oder NetraMark) (CSE: AIAI) (OTCQB: AINMF) (FWB: PF0), ein führendes Unternehmen für künstliche Intelligenz......
22.09.25 - 14:33
 NetraMark Initiates AI-Driven Collaboration in Glioblastoma Research (GlobeNewswire EN)
 
TORONTO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced a new collaboration focused on glioblastoma (GBM) research. The collaboration, supported by a license to proprietary know-how, grants NetraMark access to clinical and biomarker datasets from a leading U.S. academic medical center....
12.08.25 - 14:33
 NetraMark Appoints Jan Sedway as Senior Vice President of Clinical Science to Accelerate Growth and Market Leadership (GlobeNewswire EN)
 
TORONTO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt:PF0) a premier artificial intelligence (AI) company transforming clinical trials today announced the appointment of Jan Sedway, Ph.D., as Senior Vice President of Clinical Science....
05.08.25 - 14:36
 Asklepion Pharmaceuticals unterzeichnet Vertrag zur Nutzung der NetraMark-Technologie im Rahmen seiner Phase-III-Studie zu pädiatrischen Herzerkrankungen (IRW Press)
 
TORONTO, ON, 5. AUGUST 2025 / IRW-Press / NetraMark Holdings Inc. (das Unternehmen oder NetraMark) (CSE: AIAI) (OTCQB: AINMF) (FWB: PF0), ein führendes Unternehmen für Künstliche Intelligenz (KI),......
05.08.25 - 14:18
 Asklepion Pharmaceuticals Signs Contract to Utilize NetraMark Technology in Phase III Pediatric Cardiac Study (GlobeNewswire EN)
 
TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials today announced it has signed a contract with Asklepion Pharmaceuticals to deploy its NetraAI platform to analyze results from its pivotal Phase III pediatric clinical trial....
31.07.25 - 14:18
 NetraMark to Attend Canaccord Genuity′s 45th Annual Growth Conference (GlobeNewswire EN)
 
TORONTO, July 31, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials is pleased to announce that its Chief Executive Officer, George Achilleos, will be attending the 45th Annual Growth Conference hosted by Canaccord Genuity, taking place August 12–14, 2025, in Boston, Massachusetts....
30.07.25 - 14:48
 NetraMark gibt Partnerschaft mit Pentara bekannt, die der Erkennung von Verhaltensanomalien in Prüfzentren und bei Studienteilnehmern sowie der Gewährleistung der Integrität klinischer Studien dient (IRW Press)
 
TORONTO, ON, 30. JULI 2025 / IRW-Press / NetraMark Holdings Inc. (das Unternehmen oder NetraMark) (CSE: AIAI) (OTCQB: AINMF) (FWB: PF0), ein führendes Unternehmen für künstliche Intelligenz (KI), das......
30.07.25 - 13:15
 NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity (GlobeNewswire EN)
 
TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and Pentara Corporation (“Pentara”), a company offering clinical data analysis services to the pharmaceutical and biotechnology industries today announced they have entered into an agreement....
28.07.25 - 14:24
 NetraMark unterzeichnet mit Algo Tx Vertrag zur Optimierung des Designs der klinischen Studie ATX01 (IRW Press)
 
TORONTO, ON, 28. JULI 2025 / IRW-Press / NetraMark Holdings Inc. (das Unternehmen oder NetraMark) (CSE: AIAI) (OTCQB: AINMF) (FWB: PF0), ein führendes Unternehmen für künstliche Intelligenz (KI), das......
28.07.25 - 14:03
 NetraMark Signs Contract with AlgoTx to Enhance Clinical Trial Design for ATX01 (GlobeNewswire EN)
 
TORONTO, July 28, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and AlgoTherapeutix SAS ("AlgoTx"), a clinical-stage biotechnology company developing first-in-class therapies for chemotherapy-induced peripheral neuropathy (CIPN) today announced they have entered into an agreement....
23.06.25 - 14:42
 KI von NetraMark ist ChatGPT, DeepSeek und herkömmlichen Modellen des maschinellen Lernens bei der Ermittlung von Untergruppen in klinischen Studien klar überlegen und eröffnet einen neuen erfolgversprechenden Studienansatz (IRW Press)
 
TORONTO, ON, 23. JUNI 2025 / IRW-Press / NetraMark Holdings Inc. (das Unternehmen oder NetraMark) (CSE: AIAI) (OTCQB: AINMF) (FWB: PF0), ein führendes Unternehmen für Künstliche Intelligenz (KI), das......
23.06.25 - 14:33
 NetraMark′s AI Significantly Outperforms ChatGPT, DeepSeek and Traditional Machine Learning in Clinical Trial Subpopulation Discovery, Offers New Path for Trial Success (GlobeNewswire EN)
 
TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials has released a new preprint on arXiv demonstrating that its flagship AI platform, NetraAI, has substantially outperformed leading large language models, DeepSeek and ChatGPT. NetraAI also outperformed traditional machine learning techniques in identifying clinically meaningful patient subgroups from real-world clinical trial data....
12.06.25 - 14:15
 NetraMark Founder Coauthors New Publication on AI/ML Use in Clinical Trials, Alongside Authors From Leading Global Regulatory Organizations (GlobeNewswire EN)
 
TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) solutions company transforming clinical trial design in the pharmaceutical industry through streamlined access to actionable analytics uncovered by AI, today announced that NetraMark founder Dr. Joseph Geraci was the lead author on a new publication that outlines the market opportunity for AI/ML to improve data quality and patient outcomes in clinical development....
10.06.25 - 22:30
 NetraMark Completes 2025 Annual General Meeting (GlobeNewswire EN)
 
NETRAMARK COMPLETES 2025 ANNUAL GENERAL MEETING...
10.04.25 - 22:12
 NETRAMARK TO HOST SHAREHOLDER CONFERENCE CALL TO DISCUSS BUSINESS MOMENTUM (PR Newswire)
 
TORONTO, April 10, 2025 /PRNewswire/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry,......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Auf den Universitäten lernen die Wirtschaftsstudenten immer nur investieren. Fürs Schrumpfen haben die noch keinen Lehrstuhl. - Dr. Oskar Grünwald
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!